These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25226867)

  • 1. Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li-Fraumeni syndrome.
    Etzold A; Schröder JC; Bartsch O; Zechner U; Galetzka D
    Fam Cancer; 2015 Mar; 14(1):161-5. PubMed ID: 25226867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
    Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
    Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation.
    Yamazaki F; Shima H; Osumi T; Narumi S; Kuroda T; Shimada H
    J Pediatr Hematol Oncol; 2018 Apr; 40(3):e195-e197. PubMed ID: 28902083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
    Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
    BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.
    van Hest LP; Ruijs MW; Wagner A; van der Meer CA; Verhoef S; van't Veer LJ; Meijers-Heijboer H
    Fam Cancer; 2007; 6(3):311-6. PubMed ID: 17318340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
    Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
    Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rare
    Powers J; Pinto EM; Barnoud T; Leung JC; Martynyuk T; Kossenkov AV; Philips AH; Desai H; Hausler R; Kelly G; Le AN; Li MM; MacFarland SP; Pyle LC; Zelley K; Nathanson KL; Domchek SM; Slavin TP; Weitzel JN; Stopfer JE; Garber JE; Joseph V; Offit K; Dolinsky JS; Gutierrez S; McGoldrick K; Couch FJ; Levin B; Edelman MC; Levy CF; Spunt SL; Kriwacki RW; Zambetti GP; Ribeiro RC; Murphy ME; Maxwell KN
    Cancer Res; 2020 Sep; 80(17):3732-3744. PubMed ID: 32675277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
    Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
    Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
    Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
    Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report : Li-Fraumeni Syndrome with Central Nervous System Tumors in Two Siblings.
    Fang Z; Su Y; Sun H; Ge M; Qi Z; Hao C; Qian S; Ma X
    BMC Pediatr; 2021 Dec; 21(1):588. PubMed ID: 34961499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
    Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
    Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
    Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
    Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
    Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
    Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining.
    MacGeoch C; Turner G; Bobrow LG; Barnes DM; Bishop DT; Spurr NK
    J Med Genet; 1995 Mar; 32(3):186-90. PubMed ID: 7783166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.